BioCardia reports Q3 net loss $8.9M, DSMB supports adaptive design for heart failure trial

BioCardia, Inc.

9-month revenue $1.2M (up from $0.9M), net loss $8.9M, operating cash burn $7.6M.
CardiAMP heart failure trial DSMB recommends adaptive statistical plan for early readout; 100% survival at 2 years in roll-in cohort.
IND filed for NK1R+ MSC for heart failure (BCDA-03); FDA approval anticipated Dec 2022.
First manufacturing batch for ARDS program (BCDA-04) completed; first patient treatment expected Q4 2022.
BlueRock partnership for cell delivery; upfront payment received, option for worldwide license.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioCardia, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-026593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.